These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

145 related items for PubMed ID: 22833373

  • 1. Rituximab in psoriatic arthritis: an exploratory evaluation.
    Jimenez-Boj E, Stamm TA, Sadlonova M, Rovensky J, Raffayová H, Leeb B, Machold KP, Graninger WB, Smolen JS.
    Ann Rheum Dis; 2012 Nov; 71(11):1868-71. PubMed ID: 22833373
    [Abstract] [Full Text] [Related]

  • 2. Rituximab treatment for spondyloarthritis. A nationwide series: data from the AIR registry of the French Society of Rheumatology.
    Wendling D, Dougados M, Berenbaum F, Brocq O, Schaeverbeke T, Mazieres B, Marcelli C, Leparc JM, Bertin P, Robin M, Sibilia J, Lafforgue P, Prati C, Combe B, Gottenberg JE, French Society of Rheumatology and the Club Rhumatismes et Inflammation.
    J Rheumatol; 2012 Dec; 39(12):2327-31. PubMed ID: 22896028
    [Abstract] [Full Text] [Related]

  • 3. Sustained benefits of infliximab therapy for dermatologic and articular manifestations of psoriatic arthritis: results from the infliximab multinational psoriatic arthritis controlled trial (IMPACT).
    Antoni CE, Kavanaugh A, Kirkham B, Tutuncu Z, Burmester GR, Schneider U, Furst DE, Molitor J, Keystone E, Gladman D, Manger B, Wassenberg S, Weier R, Wallace DJ, Weisman MH, Kalden JR, Smolen J.
    Arthritis Rheum; 2005 Apr; 52(4):1227-36. PubMed ID: 15818699
    [Abstract] [Full Text] [Related]

  • 4. Comparative effectiveness of switching to alternative tumour necrosis factor (TNF) antagonists versus switching to rituximab in patients with rheumatoid arthritis who failed previous TNF antagonists: the MIRAR Study.
    Gomez-Reino JJ, Maneiro JR, Ruiz J, Roselló R, Sanmarti R, Romero AB, MIRAR Study Group.
    Ann Rheum Dis; 2012 Nov; 71(11):1861-4. PubMed ID: 22736086
    [Abstract] [Full Text] [Related]

  • 5. Highest clinical effectiveness of rituximab in autoantibody-positive patients with rheumatoid arthritis and in those for whom no more than one previous TNF antagonist has failed: pooled data from 10 European registries.
    Chatzidionysiou K, Lie E, Nasonov E, Lukina G, Hetland ML, Tarp U, Gabay C, van Riel PL, Nordström DC, Gomez-Reino J, Pavelka K, Tomsic M, Kvien TK, van Vollenhoven RF.
    Ann Rheum Dis; 2011 Sep; 70(9):1575-80. PubMed ID: 21571731
    [Abstract] [Full Text] [Related]

  • 6. Responses to adalimumab in patients with active psoriatic arthritis who have not adequately responded to prior therapy: effectiveness and safety results from an open-label study.
    Gladman DD, ACCLAIM Study Investigators, Sampalis JS, Illouz O, Guérette B.
    J Rheumatol; 2010 Sep; 37(9):1898-906. PubMed ID: 20595284
    [Abstract] [Full Text] [Related]

  • 7. Comparative effectiveness of rituximab in combination with either methotrexate or leflunomide in the treatment of rheumatoid arthritis.
    Narváez J, Díaz-Torné C, Ruiz JM, Hernández MV, Torrente-Segarra V, Ros S, Rodriguez de la Serna A, Díaz-López C, Sanmartí R, Nolla JM.
    Semin Arthritis Rheum; 2011 Dec; 41(3):401-5. PubMed ID: 21862107
    [Abstract] [Full Text] [Related]

  • 8. Safety and effectiveness of rituximab in patients with rheumatoid arthritis following an inadequate response to 1 prior tumor necrosis factor inhibitor: the RESET Trial.
    Haraoui B, Bokarewa M, Kallmeyer I, Bykerk VP, RESET Investigators.
    J Rheumatol; 2011 Dec; 38(12):2548-56. PubMed ID: 21965646
    [Abstract] [Full Text] [Related]

  • 9. Treatment of psoriatic arthritis and psoriasis vulgaris with the tumor necrosis factor inhibitor infliximab.
    Cauza E, Spak M, Cauza K, Hanusch-Enserer U, Dunky A, Wagner E.
    Rheumatol Int; 2002 Nov; 22(6):227-32. PubMed ID: 12426660
    [Abstract] [Full Text] [Related]

  • 10. Predictive factors of rituximab response in rheumatoid arthritis: results from a French university hospital.
    Couderc M, Mathieu S, Pereira B, Glace B, Soubrier M.
    Arthritis Care Res (Hoboken); 2013 Apr; 65(4):648-52. PubMed ID: 23045227
    [Abstract] [Full Text] [Related]

  • 11. Effectiveness of rituximab in patients with rheumatoid arthritis: observational study from the British Society for Rheumatology Biologics Register.
    Soliman MM, Hyrich KL, Lunt M, Watson KD, Symmons DP, Ashcroft DM, British Society for Rheumatology Biologics Register.
    J Rheumatol; 2012 Feb; 39(2):240-6. PubMed ID: 22174201
    [Abstract] [Full Text] [Related]

  • 12. Composite measures in psoriatic arthritis: GRAPPA 2008.
    Gladman DD, Landewé R, McHugh NJ, Fitzgerald O, Thaci D, Coates L, Mease PJ, Qureshi AA, Krueger GG, Ritchlin CT, Kavanaugh AF, Garg A.
    J Rheumatol; 2010 Feb; 37(2):453-61. PubMed ID: 20147481
    [Abstract] [Full Text] [Related]

  • 13. Effectiveness of psoriatic arthritis therapies.
    Gladman DD.
    Semin Arthritis Rheum; 2003 Aug; 33(1):29-37. PubMed ID: 12920694
    [Abstract] [Full Text] [Related]

  • 14. Infliximab improves signs and symptoms of psoriatic arthritis: results of the IMPACT 2 trial.
    Antoni C, Krueger GG, de Vlam K, Birbara C, Beutler A, Guzzo C, Zhou B, Dooley LT, Kavanaugh A, IMPACT 2 Trial Investigators.
    Ann Rheum Dis; 2005 Aug; 64(8):1150-7. PubMed ID: 15677701
    [Abstract] [Full Text] [Related]

  • 15. Comparison of two etanercept regimens for treatment of psoriasis and psoriatic arthritis: PRESTA randomised double blind multicentre trial.
    Sterry W, Ortonne JP, Kirkham B, Brocq O, Robertson D, Pedersen RD, Estojak J, Molta CT, Freundlich B.
    BMJ; 2010 Feb 02; 340():c147. PubMed ID: 20124563
    [Abstract] [Full Text] [Related]

  • 16. Effectiveness and safety of etanercept in patients with psoriatic arthritis in a Canadian clinical practice setting: the REPArE trial.
    Gladman DD, Bombardier C, Thorne C, Haraoui B, Khraishi M, Rahman P, Bensen W, Syrotuik J, Poulin-Costello M.
    J Rheumatol; 2011 Jul 02; 38(7):1355-62. PubMed ID: 21572156
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Efficacy and tolerability of anti-tumour necrosis factor therapy in psoriatic arthritis patients: results from the South Swedish Arthritis Treatment Group register.
    Kristensen LE, Gülfe A, Saxne T, Geborek P.
    Ann Rheum Dis; 2008 Mar 02; 67(3):364-9. PubMed ID: 17644547
    [Abstract] [Full Text] [Related]

  • 19. Application of the DAREA/DAPSA score for assessment of disease activity in psoriatic arthritis.
    Schoels M, Aletaha D, Funovits J, Kavanaugh A, Baker D, Smolen JS.
    Ann Rheum Dis; 2010 Aug 02; 69(8):1441-7. PubMed ID: 20525844
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.